Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI study of Cefiderocol and Midazolam
NCT05395104Phase 1Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- May 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cefiderocol in bacterial infection, sponsored by Shionogi & Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration of Midazolam at Day 15, Time to Maximum Plasma Concentration of Midazolam at Day 15 and 5 more. Started May 2022; status: completed.
02
Drugs
cefiderocol
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT05395104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05395104.